News FDA looks at Opdivo/Yervoy in first-line colorectal cancer The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.
News NICE backs consolidation use of Blincyto in leukaemia NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.
News Poolbeg slumps as Hookipa merger is called off A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.
News NICE changes its mind on BMS' lymphoma cell therapy Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.
News Boehringer eyes third quarter FDA verdict for oral HER2 drug Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
News BMS study of Opdualag in adjuvant melanoma ends in failure Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.